Navigation Links
Breast cancer cells growing in 3D-matrix revert to normal
Date:12/17/2012

Human breast cancer cells growing in the lab on a three-dimensional (3-D) extracellular matrix reverted to a normal phenotype when subjected to compression force applied by an elastic chamber, researchers reported on Dec. 17 at the American Society for Cell Biology Annual Meeting in San Francisco.

Gautham Venugopalan, PhD, of the University of California, Berkeley, bioengineering lab of Daniel Fletcher, PhD, described how applying compressive force to malignant breast epithelial cells growing within a laminin-rich 3-D extracellular matrix caused them to turn into highly organized, growth-arrested acini, the milk-secreting spherical structures that are central to breast tissue.

This "phenotypic reversion" was accomplished without pharmacological agents, noted Dr. Venugopalan. Research collaborators included Kandice Tanner, PhD, and Mina Bissell, PhD, of the Lawrence Berkeley National Laboratory in Berkeley.

During a woman's reproductive life, breast tissue continuously grows, shrinks, and remodels in a highly regulated fashion. When this process breaks down, growth becomes abnormal.

Although genetic mutations are the classic explanation for differences between healthy and malignant cells but they don't tell the whole story because malignant cells treated with certain drugs will grow into organized acini that appear very similar to the healthy acini, even though they remain genetically malignant. This indicates that malignant cells have not completely "forgotten" how to be healthy, since they can be guided back into their "normal" growth program by giving them the right cues, according to Dr. Venugopalan.

Could mechanical force also reprogram malignant cells? The researchers seeded malignant breast epithelial cells into a 3-D laminin-rich extracellular matrix and used an elastic chamber to apply a compressive force. Over time, the compressed malignant cells grew into more organized, healthy-looking acini that resembled normal structures, even without the addition of exogenous drugs.

However, when the researchers added a drug that blocked E-cadherin, a transmembrane protein that helps cells adhere to their neighbors, the compression lost all effect, and the cells returned to their disorganized malignant appearance.

Previous studies have shown that healthy breast cells rotate as they form acini to help them organize into spherical structures, according to Dr. Venugopalan. This coherence is lost in malignant cells, so the researchers investigated whether rotation was affected by compression. By performing time-lapse microscopy over several days, they found that compression was inducing rotation in the malignant cells, further suggesting the importance of cell-cell communication during growth.

"Our findings suggest that external forces can encourage malignant cells to re-enter the correct morphogenetic program," said Dr. Venugopalan.
'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814

John Fleischman
jfleischman@ascb.org
513-706-0212

American Society for Cell Biology
Source:Eurekalert


Related biology technology :

1. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
2. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
3. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
4. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
5. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
6. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
7. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
8. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
9. Silicone Scandal: Stem Cell Breast Augmentation a Safe Alternative
10. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
11. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a ... Board. Dr. Lamka will assist PathSensors in expanding the use of the company‚Äôs ... the CANARY® test platform for the detection of harmful pathogens, including a number ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, ... Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from ... and the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on ... of Catherine Moukheibir as Chairman of its Board of Directors. ... Jacques Garaud , who contributed to the rapid development of ... Catherine started her career in strategy consulting and investment ... London .  She held C-Suite level roles in some ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):